Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Massachusetts: - Tufts Medical Center — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
Phase 2 Recruiting NIH
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Sites in Massachusetts: - Boston Medical Center — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Network
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…
Sponsor: Children's Oncology Group
NCT ID: NCT06620302
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
Sponsor: Allison O'Neill, MD
NCT ID: NCT04134559
Sites in Massachusetts: - Children's Hospital Boston — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and ha…
Sponsor: Eureka Therapeutics Inc.
NCT ID: NCT04634357
Sites in Massachusetts: - Dana-Farber/Boston Children's Cancer and Blood Disorders Center — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer. The interventions involved in this study are: * Durvalumab * Tremelimumab * Radiation Therapy
Sponsor: Massachusetts General Hospital
NCT ID: NCT03482102
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Massachusetts: - Exelixis Clinical Site #7 — Boston, Massachusetts
Phase 1 Recruiting Industry
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocel…
Sponsor: Tyra Biosciences, Inc
NCT ID: NCT06915753
Sites in Massachusetts: - Mass General Cancer Center — Boston, Massachusetts
Phase 1 Recruiting Industry
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Sponsor: SEED Therapeutics, Inc.
NCT ID: NCT07197554
Sites in Massachusetts: - Mass General Brigham Cancer Institute — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1 Recruiting Academic/Other
This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma. This study involves the following i…
Sponsor: Massachusetts General Hospital
NCT ID: NCT05096715
Sites in Massachusetts: - Massachusetts General Hospital Cancer Center — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 1 Recruiting Academic/Other
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC)…
Sponsor: Jiping Wang, MD, PhD
NCT ID: NCT05701488
Sites in Massachusetts: - Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Massachusetts: - Massive Bio SYNERGY-AI site — Worcester, Massachusetts
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Massachusetts: - Holyoke Medical Center — Holyoke, Massachusetts
Phase 4 Recruiting Academic/Other
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection…
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT06084234
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
NA Recruiting Federal
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HC…
Sponsor: VA Office of Research and Development
NCT ID: NCT05486572
Sites in Massachusetts: - VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA — Boston, Massachusetts
Phase 4 Recruiting Industry
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x…
Sponsor: Guerbet
NCT ID: NCT04373564
Sites in Massachusetts: - Massachussets General Hospital — Boston, Massachusetts
- Boston University Medical Center — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- ActivMed Practices & Research, Inc. — Methuen, Massachusetts
- University of Massachusetts Memorial Medical Center — Worcester, Massachusetts
NA Recruiting Academic/Other
This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.
Sponsor: Brigham and Women's Hospital
NCT ID: NCT04545957
Sites in Massachusetts: - Brigham and Women Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
NA Recruiting Academic/Other
This study aims to refine and pilot test HARMONY, a psychoeducational intervention for patients with newly diagnosed hepatocellular carcinoma (HCC).
Sponsor: Massachusetts General Hospital
NCT ID: NCT06541990
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
Recruiting Academic/Other
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reprod…
Sponsor: Massachusetts General Hospital
NCT ID: NCT06265272
Sites in Massachusetts: - Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School — Charlestown, Massachusetts